To overcome the resistance of PD-1/PD-L1 targeted immunotherapy in pancreatic cancer, further studies are required to modulate the TME consisting of immunosuppressive cells such as Tregs, MDSCs, and TAMs. This evidence concerns the gene CD274 and familial pancreatic carcinoma.